Financial Contrast: Can-Fite BioPharma (NYSE:CANF) & TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Institutional and Insider Ownership

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares TherapeuticsMD and Can-Fite BioPharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	7.39	-$570,000.00	$0.02	96.50
Can-Fite BioPharma	$405,000.00	4.89	-$7.63 million	($14.80)	-0.12

TherapeuticsMD has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for TherapeuticsMD and Can-Fite BioPharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
Can-Fite BioPharma	0	1	2	0	2.67

Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 2,278.38%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than TherapeuticsMD.

Profitability

This table compares TherapeuticsMD and Can-Fite BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Can-Fite BioPharma	N/A	N/A	N/A

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.